Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Combination Therapy for Autoimmune Connective Tissue Diseases: Dermatomyositis, Lupus, and Systemic Sclerosis
Description
The talk emphasized that autoimmune connective tissue diseases often require combination therapy because single agents rarely control the complex interplay of B cells, T cells, cytokines, and type I interferon pathways. For dermatomyositis, the speaker reviewed a stepwise approach starting with sun protection and conventional agents such as methotrexate, mycophenolate, and hydroxychloroquine, then escalating to IVIG, rituximab, cyclosporine, and early rituximab for severe MDA5 disease. She highlighted emerging benefit from apremilast, JAK inhibitors such as ruxolitinib, tofacitinib, and baricitinib, and the newer JAK1/TYK2 inhibitor brepocitinib, which improved global disease scores, skin activity, and steroid tapering with an acceptable safety profile, though infection remains the key concern. She also discussed anifrolumab, an interferon receptor blocker approved for lupus, as a promising add-on in dermatomyositis. For non-renal lupus, standard measures included sun protection, smoking cessation, hydroxychloroquine, and add-on methotrexate, azathioprine, or mycophenolate, with belimumab, anifrolumab, cyclophosphamide, or rituximab for more severe disease; JAK inhibitors such as baricitinib and deucravacitinib also showed skin and joint benefit, again with infection monitoring. In systemic sclerosis and morphea, mycophenolate, methotrexate, rituximab, tocilizumab, vasodilators, and emerging JAK inhibition were discussed, with tofacitinib showing better skin score improvement than methotrexate in one study. Overall, the message was to use layered therapy thoughtfully, monitor closely for infection and other toxicities, and taper steroids whenever possible to reach the goal of simpler, safer control.
View moreConclusions
- For dermatomyositis, combination therapy appears more effective than single-agent treatment for refractory disease, with especially strong improvements in cutaneous activity.
- JAK inhibitors and TYK2 inhibitors show consistent benefit in dermatomyositis, particularly for skin disease, and may also help lung involvement and steroid tapering.
- Adding apremilast to background immunosuppressive therapy can produce marked clinical improvement in recalcitrant dermatomyositis, with mostly manageable adverse effects.
- Anifrolumab and other interferon-pathway blockers may be useful adjuncts in difficult dermatomyositis and lupus cases, especially when used with standard background therapy.
- In non-renal systemic lupus erythematosus, hydroxychloroquine remains foundational, but layered treatment with immunosuppressants, biologics, or JAK/TYK2 inhibitors can improve disease control.
- Deucravacitinib shows promising efficacy in lupus, including improvements in cutaneous and systemic response measures, without major laboratory toxicity signals in the trial presented.
- For systemic sclerosis and morphea, combination treatment is often necessary because the disease is fibrotic and multisystem, and adding targeted agents may improve skin and ulcer outcomes.
- Tofacitinib and other JAK inhibitors may improve skin fibrosis and digital ulcers in systemic sclerosis more than methotrexate in early studies.
- Patients who receive JAK inhibitors earlier in fibrotic connective tissue disease may do better than those treated only after multiple prior failures.
- Across connective tissue diseases, the practical goal is not to avoid combination therapy, but to use it thoughtfully with close monitoring for infection, adverse events, and eventual steroid and medication tapering when disease becomes stable.
- Wahren-Herlenius et al. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013 Aug 31;382(9894):819-31.#10.1016/s0140-6736(13)60954-x
- Bitar et al. Apremilast in Recalcitrant Cutaneous Dermatomyositis A Nonrandomized Controlled Trial JAMA Dermatol. 2022;158(12):1357-1366.#10.1001/jamadermatol.2022.3917
- Hornung et al. N Engl J Med. 2014 Dec 25;371(26):2537-8.
- Chenhang et al. 2024 Frontiers in Immunology meta-analysis on JAK-inhibitors in dermatomyositis.
- Vleugels et al. A Phase 3 Trial of Brepocitinib in Dermatomyositis. Published March 28, 2026. DOI: 10.1056/NEJMoa2503531.#10.1056/NEJMoa2503531
- Rahbek et al. Anifrolumab for refractory dermatomyositis: a case series. Scand J Rheumatol. 2025 Sep;54(5):387-389.#10.1080/03009742.2025.2503573
- Fanouriakis et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83:15–29.
- Morand et al. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2023 Feb;75(2):242-252.
- Del Gado et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025 Jan;84(1):29-40.#10.1136/ard-2024-226430
- Jerjen et al. Systemic sclerosis in adults. Part II: management and therapeutics. J Am Acad Dermatol. 2022 Nov;87(5):957-978. doi: 10.1016/j.jaad.2021.10.066.#10.1016/j.jaad.2021.10.066
- Karalilova et al. Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound Rheumatol Int. 2021 Oct;41(10):1743-1753.#10.1007/s00296-021-04956-7